Aura Biosciences
AURA
94 hedge funds and large institutions have $324M invested in Aura Biosciences in 2024 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 39 increasing their positions, 15 reducing their positions, and 9 closing their positions.
160% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 15
144% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 9
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
16% more funds holding
Funds holding: 81 → 94 (+13)
4.67% more ownership
Funds ownership: 74.31% → 78.98% (+4.7%)
1% less capital invested
Capital invested by funds: $329M → $324M (-$4.91M)
94% less call options, than puts
Call options by funds: $16K | Put options by funds: $255K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$13.2M |
| 2 |
LCS
Levin Capital Strategies
New York
|
+$7.85M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$6.26M |
| 4 |
BlackRock
New York
|
+$3.68M |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$1.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$16.2M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$656K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$656K |
| 4 |
RCM
Regency Capital Management
Honolulu,
Hawaii
|
-$545K |
| 5 |
D.E. Shaw & Co
New York
|
-$338K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NC
101
nVerses Capital
Wellington,
Florida
| – | -$3.56K | -400 | Closed |
|
102
Group One Trading
Chicago,
Illinois
| – | -$1.68K | -189 | Closed |
|
|
CPA
103
Capital Performance Advisors
Walnut Creek,
California
| – | -$223 | -25 | Closed |
|
AURA Hedge Fund Activity: Q4 2024 in Review
94 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Aura Biosciences (AURA) for Q4 2024, worth a combined $324M — down 1.5% from $329M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new AURA positions and 9 closed out — a net gain of 13 holders — while 39 added to existing stakes and 15 trimmed.
The largest buyer was Long Focus Capital Management, adding an estimated $13.2M. The largest seller was Eventide Asset Management, cutting an estimated $16.2M.
- 94 institutional investors held Aura Biosciences (AURA) as of Q4 2024, up from 81 in Q3 2024.
- Funds reported $324M of Aura Biosciences stock for Q4 2024, down 1.5% quarter-over-quarter.
- 22 funds opened new Aura Biosciences positions in Q4 2024 and 9 closed out, a net change of +13 holders.
- The largest Aura Biosciences buyer in Q4 2024 was Long Focus Capital Management, an estimated $13.2M added.
- The largest Aura Biosciences seller in Q4 2024 was Eventide Asset Management, an estimated $16.2M sold.
Based on aggregated 13F filings for Q4 2024.